Nootropic, neuroprotective, and cognitive compounds.

Cognitive and nootropic research peptides are neuroactive sequences (including ACTH-derived fragments and N-acetylated variants) studied in preclinical research models for receptor-binding behavior, neurotransmission signaling, and neurotrophic factor modulation. The Nexus catalog includes 12 compounds in this category — examples: Selank, Semax, NA Selank amidate, NA Semax amidate, Semax 10mg+Selank 10mg. Supplied for in-vitro research use only. Cognitive and nootropic research products include neuroactive peptides, Semax and Selank families, amidated variants, and adjacent neural-signaling compounds. Nexus groups them for researchers comparing stress-response, cognition, sleep-adjacent, and neuroprotection models. The category includes Selank, Semax, NA-Selank Amidate, NA-Semax Amidate, Semax + Selank blends, Cerebrolysin, DSIP, P21 variants, PE-22-28, PTD-DBM, and N-Acetyl Epitalon Amidate.

Researchers in this group often evaluate sequence modifications, neuropeptide family relationships, and pathway-adjacent comparisons. Amidated variants should be reviewed as separate catalog identities from their base names because terminal modification affects the research record. Nexus keeps the language factual by focusing on compound families, variant options, and lab context. Product pages link related compounds so users can move between Semax, Selank, and blend formats without relying on broad marketing claims.

Nexus prioritizes product identity, COA visibility, HPLC verification where available, and clear research-only positioning. Modified variants are listed separately to reduce ambiguity in search and internal linking.

Compounds in this category are studied in preclinical research models examining neuropeptide receptor binding, neurotrophic factor signaling, neurotransmission research, and CNS pharmacology. Common research applications include selank and semax (Russian ACTH-fragment and TP-7-derived peptides) research on neurotrophic factor signaling; their N-acetylated amidate variants (NA-selank-amidate, NA-semax-amidate) for stability-extended research; cerebrolysin research on neuropeptide-pool signaling; DSIP research on circadian and sleep pathway research; P21 (with and without adamantane) research on ciliary neurotrophic factor signaling; PE 22-28 research on spadin-pathway research; and PTD-DBM research on Dvl PDZ-domain binding.

The 12 compounds in this category span seven mechanism sub-families: ACTH-fragment analogs (semax, NA-semax-amidate), TP-7-derived peptides (selank, NA-selank-amidate, plus the semax+selank blend), neuropeptide pools (cerebrolysin), sleep-axis peptides (DSIP), ciliary neurotrophic factor-derived peptides (P21 variants), spadin analogs (PE 22-28), Dvl PDZ-binding peptides (PTD-DBM), and pineal-axis modified peptides (N-acetyl-epitalon-amidate).

Canonical stack pairing within this category: selank + semax, available standalone or as the pre-formulated semax+selank 10mg+10mg research blend. NA-selank-amidate + NA-semax-amidate provides the modified-variant complement. Cross-family pairings with Khavinson bioregulators (cortagen, pinealon, epithalon) extend the CNS-axis research scope.

Most compounds in this category are short peptides (4-9 residues) characterized by standard reverse-phase HPLC and ESI-MS. Cerebrolysin is a neuropeptide-pool product — its composition is verified by amino acid analysis and molecular-weight distribution rather than a single-peak HPLC purity.